(AOF) – The Valneva vaccine specialist (-3.48% to 2.82 euros) awarded the highest drop in SBF 120 yesterday. This withdrawal intervened while the European Medicines Agency (EMA) suspended the use of the IXCHIQ vaccine, intended to prevent the disease caused by the chikungunya virus, for people over 65.
For its part, Valneva “continues to estimate that the benefit/risk ratio of the vaccine is positive for the vast majority of people potentially exposed to the disease”.
AOF – Find out more
Key points
– Specialist in the development of prophylactic vaccines against infectious diseases with limited therapeutic options;
-turnover of € 153.7 MD MD from Europe for 56 %, ahead of America (27 %), then Asia-Oceania (9 %) and Africa-Middle-East (8 %);
– ambition to create diseases against diseases without existing solutions with 2 main stages, 2024 for the marketing of the vaccine against chikungunya IXCHIQ and 2027 for that of the Lyme disease vaccine;
– Capital held at 6.2 % (10.36 % of voting rights) by the Grimaud La Corbière group and 6.22 % by BPI France, Anne-Marie Graffin presiding over the council of 6 administrators and Thamas Langelbach ensuring the general management;
– Towards a change in governance by the end of the year, for a board of directors and executive committee.
Challenges
– Agility of the business model:
– Control of the value chain, from research to marketing,
– Promotion of group assets by partnerships,
– Funding of clinical developments by a specialized infrastructure for the marketing of 3 commercial vaccines (Ixiaro against Japanese encephalitis, Ixchiq against chikungunya and dukoral against cholera) and by the rights drawn from the distribution of vaccines for third parties,
– financial security, cash flow covering operational needs until 2027,
-– Innovation rich in a portfolio of + 400 patents with 2 main assets and 3 preclinical programs: the only vaccine in clinical development against Lyme disease, the only vaccine with unique injection against chikungunya, and 3 candidates vaccines against the Zika virus, the Epstein-Barr virus and the human metapneumovirus;
– Environmental strategy: energy efficiency, waste minimization, optimal water use and 5 %reduction, vs 2016, CO2 emissions by 2025;
– Good visibility of the activity thanks to the agreements on vaccines with:
– With Pfizer to co-develop and sell the Lyme disease vaccine ($ 308 million),
– With the American authorities for Ixiario against Japanese encephalitis ($ 70 million),
– With Bavarian Nordic for marketing and distribution of specialized vaccines,
– With Batavia Biosciences to develop an inexpensive vaccine against polio,
– with the Butantan Institute against Chikingunya for low -income countries;
– Solid assessment with € 128 million in equity, reinforced by a net cash of € 126 million at the end of March.
Challenge
– La launch trade results, secured by private financing of € 100 million and by a contribution of + $ 40 million in the CEPI and the European Union, the IXCHIQ vaccine, the only world vaccine authorized against chikungunya authorized by Canada and the European Union;
– Results of phase 3 tests for the Lyme disease vaccine after completed recruitment, in partnership with Pfizer which will file a request in 2026;
– Search for partnerships for the search for men’s metapneumovirus vaccine and extension of the manufacturing network (3 sites, in Scotland, Sweden and Austria),
– After a 1
is
Positive quarter (€ 177 million in cash and net profit of € 59 million after sale products), target 2024 Record: turnover between € 170 and € 180 million and R&D expenses between € 60 and € 75 million;
.- Objective 2026 to achieve net profitability thanks to the doubling of sales, drawn by Ixchiq and Ixiaro, before those of the Lyme vaccine expected on the market in 2027.
